-
EP4004208
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4004208
| EP4004208 - APTAMER-BASED MULTISPECIFIC THERAPEUTIC AGENTS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 29.04.2022 Database last updated on 16.07.2024 | |
| Former | The international publication has been made Status updated on 05.02.2021 | ||
| Former | unknown Status updated on 26.08.2020 | Most recent event Tooltip | 16.01.2024 | New entry: Additional fee for renewal fee: payment of fee | 16.01.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states IXAKA FRANCE 1 Mail du Professeur Georges Mathé 94800 Villejuif / FR | [2022/22] | Inventor(s) | 01 /
MIODEK, Anna 13 rue Archange 91400 Orsay / FR | 02 /
MOURLANE, Frédéric 17 avenue des Orangers 06000 Nice / FR | 03 /
BAUCHE, Cecile 14 rue Auguste Perret 75013 Paris / FR | 04 /
VAILLANT, Renaud 49 rue des Champs Elysées 94250 Gentilly / FR | 05 /
BISHOP, Philippe c/o Aratinga.bio, Inc. 1927 Bridgepointe Pkwy. 307 Foster City, CA 94404 / US | [2022/22] | Representative(s) | Cabinet Beau de Loménie 158, rue de l'Université 75340 Paris Cedex 07 / FR | [2022/22] | Application number, filing date | 20757658.8 | 27.07.2020 | [2022/22] | WO2020IB00623 | Priority number, date | US201962879401P | 26.07.2019 Original published format: US 201962879401 P | US201962879413P | 26.07.2019 Original published format: US 201962879413 P | WO2019IB00890 | 26.07.2019 Original published format: PCT/IB2019/000890 | [2022/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021019297 | Date: | 04.02.2021 | Language: | EN | [2021/05] | Type: | A1 Application with search report | No.: | EP4004208 | Date: | 01.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.02.2021 takes the place of the publication of the European patent application. | [2022/22] | Search report(s) | International search report - published on: | EP | 04.02.2021 | Classification | IPC: | C12N15/115, A61K31/7088, A61P35/00 | [2022/22] | CPC: |
C12N15/115 (EP,CN,KR,US);
A61K31/7088 (CN,KR,US);
A61P35/00 (CN,KR,US);
C07K14/4748 (KR);
C07K14/7051 (KR);
C12N2310/16 (EP,CN,KR,US);
C12N2310/318 (KR);
C12N2310/3519 (KR);
C12N2310/51 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/22] | Title | German: | MULTISPEZIFISCHE THERAPEUTIKA AUF APTAMER-BASIS | [2022/22] | English: | APTAMER-BASED MULTISPECIFIC THERAPEUTIC AGENTS | [2022/22] | French: | AGENTS THÉRAPEUTIQUES MULTISPÉCIFIQUES À BASE D'APTAMÈRES | [2022/22] | Entry into regional phase | 25.02.2022 | National basic fee paid | 25.02.2022 | Designation fee(s) paid | 25.02.2022 | Examination fee paid | Examination procedure | 26.05.2021 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 25.02.2022 | Amendment by applicant (claims and/or description) | 25.02.2022 | Examination requested [2022/22] | 25.02.2022 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 28.07.2022 | Renewal fee patent year 03 | 16.01.2024 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 31.07.2023 | 04 M06 Fee paid on 16.01.2024 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2010144295 (UNIV MIAMI [US], et al) [X] 1-11 * examples 1,2; claims 1,7,11-26 * [I] 12,13; | [Y]WO2017023761 (REGENERON PHARMA [US]) [Y] 12,13 * claims 12-20,40-44 *; | [Y]WO2017134158 (AMGEN RES (MUNICH) GMBH [DE]) [Y] 12,13 * claims 1-7,16-20 *; | [XY]WO2017143150 (HOPE CITY [US], et al) [X] 1-10 * example 6; claims 1,3,10,14,30-36 * [Y] 12,13; | [XP]WO2020021338 (ARATINGA BIO TNP [FR]) [XP] 1-13* example 1 *; | [X] - PASTOR FERNANDO ET AL, "Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers", MOLECULAR THERAPY, CELL PRESS, US, (201110), vol. 19, no. 10, doi:10.1038/MT.2011.145, ISSN 1525-0016, pages 1878 - 1886, XP008150757 [X] 1,2,4-9,11 * figures 1-3 * DOI: http://dx.doi.org/10.1038/mt.2011.145 | [A] - WILHEM LECONET ET AL, "Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation", MOLECULAR CANCER THERAPEUTICS, US, (20180611), vol. 17, no. 9, doi:10.1158/1535-7163.MCT-17-1138, ISSN 1535-7163, pages 1927 - 1940, XP055750868 [A] 12,13 * figure 1 * DOI: http://dx.doi.org/10.1158/1535-7163.MCT-17-1138 | [A] - MCNAMARA JAMES O ET AL, "Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras", NATURE BIOTECHNOLOGY, GALE GROUP INC., NEW YORK, US, vol. 24, no. 8, doi:10.1038/NBT1223, ISSN 1087-0156, (20060625), pages 1005 - 1015, (20060625), XP037159823 [A] 1-13 * figure 1 * DOI: http://dx.doi.org/10.1038/nbt1223 | [A] - HONG YAN LIU ET AL, "Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer", SCIENTIFIC REPORTS, (20160726), vol. 6, no. 1, doi:10.1038/srep30346, XP055750856 [A] 1-13 * figure 1 * DOI: http://dx.doi.org/10.1038/srep30346 | [A] - ZUMRUT HASAN E ET AL, "Ligand-guided selection of aptamers against T-cell Receptor-cluster of differentiation 3 (TCR-CD3) expressed on Jurkat.E6 cells", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, AMSTERDAM, NL, (20160809), vol. 512, doi:10.1016/J.AB.2016.08.007, ISSN 0003-2697, pages 1 - 7, XP029711380 [A] 1-13 * Scheme 1 * DOI: http://dx.doi.org/10.1016/j.ab.2016.08.007 | [A] - BÜHLER P ET AL, "A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20070620), vol. 57, no. 1, doi:10.1007/S00262-007-0348-6, ISSN 1432-0851, pages 43 - 52, XP019561052 [A] 1-13 * figure 1 * DOI: http://dx.doi.org/10.1007/s00262-007-0348-6 | by applicant | US5270163 | WO2016030414 | - Clin. Vaccine Immunol., vol. 17, no. 11, pages 1708 - 1717 | - Protein Expr. Purif., vol. 35, no. 1, pages 84 - 92 | - Biomed. Res. Int. 2018, (20180000), page 5809028 | - Protein Expression and Purification, (20120000), vol. 86, pages 75 - 81 | - Bioconjugate Chem., (20100000), vol. 21, pages 1134 - 1141 | - J. of Virological Methods, (20180000), vol. 257, pages 73 - 78 | - Appl Microbiol Biotechnol., (20171200), vol. 101, no. 23-24, pages 8331 - 8344 | - Virus Research, (20120000), vol. 167, pages 370 - 379 | - Veterinary Microbiology, (20110000), vol. 147, pages 162 - 169 | - Journal of Biotechnology, (20030000), vol. 102, page 177,189 | - Arch. Virol., (20080000), vol. 153, pages 1075 - 1084 | - Acta Biochimica et Biophysica Sinica, (20040000), vol. 36, no. 8, pages 541 - 547 | - J. Virol., (20040400), vol. 78, no. 7, pages 3792 - 3796 | - J. Hepatology, (20020000), vol. 37, pages 660 - 668 | - J Virol, (19940000), vol. 68, pages 4829 - 4836 | - Arch Virol, (19970000), vol. 142, pages 601 - 610 | - J. Autoimmun., (20130504), vol. 2, pages 105 - 16 | - Blood Cancer J., (20160800), vol. 6, no. 8, page e458 | - Oncotarget., (20171212), vol. 8, no. 65, pages 108584 - 108603 | - Oncotarget, (20170509), vol. 8, no. 19, pages 31368 - 31385 | - Oncotarget, (20180126), vol. 9, no. 7, pages 7487 - 7500 |